References of "Pirson, Laurence"
     in
Bookmark and Share    
Full Text
See detailRéseau Qualité des Laboratoire de l'ULg - Rapport d'activité Février 2016
Widart, Joëlle ULiege; Beauvois, Véronique ULiege; Dumont, Fabien ULiege et al

Diverse speeche and writing (2016)

Detailed reference viewed: 44 (9 ULiège)
See detailDosage de l'alcool dans le cadre de la sécurité routière : approche statistique
Pirson, Laurence ULiege

Conference (2009, October 09)

Detailed reference viewed: 26 (9 ULiège)
See detailGestion du contrôle de qualité interne
Denooz, Raphael ULiege; Pirson, Laurence ULiege

Conference (2009, February)

Detailed reference viewed: 35 (7 ULiège)
See detailBiomarqueurs en toxicologie: ADN oxydé et adduits à l'ADN
Pirson, Laurence ULiege

Conference (2008, September 05)

Detailed reference viewed: 52 (3 ULiège)
Full Text
Peer Reviewed
See detailDespite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Pirson, Laurence ULiege; Baron, Frédéric ULiege; Meuris, Nathalie ULiege et al

in Stem Cells (2006), 24(7), 1814-21

There is potential interest for combining allogeneic hematopoietic cell transplantation (HCT), and particularly allogeneic HCT with a nonmyeloablative regimen, to the tyrosine kinase inhibitor imatinib ... [more ▼]

There is potential interest for combining allogeneic hematopoietic cell transplantation (HCT), and particularly allogeneic HCT with a nonmyeloablative regimen, to the tyrosine kinase inhibitor imatinib (Glivec; Novartis, Basel, Switzerland, http://www.novartis.com) in order to maximize anti-leukemic activity against Philadelphia chromosome-positive leukemias. However, because imatinib inhibits c-kit, the stem cell factor receptor, it could interfere with bone marrow engraftment. In this study, we examined the impact of imatinib on normal progenitor cell function. Imatinib decreased the colony-forming capacity of mobilized peripheral blood human CD133(+) cells but not that of long-term culture-initiating cells. Imatinib also decreased the proliferation of cytokine-stimulated CD133(+) cells but did not induce apoptosis of these cells. Expression of very late antigen (VLA)-4, VLA-5, and CXCR4 of CD133(+) cells was not modified by imatinib, but imatinib decreased the ability of CD133(+) cells to migrate. Finally, imatinib did not decrease engraftment of CD133(+) cells into irradiated nonobese diabetic/severe combined immunodeficient/beta2m(null) mice conditioned with 3 or 1 Gy total body irradiation. In summary, our results suggest that, despite inhibition of hematopoietic progenitor cell growth in vitro, imatinib does not interfere with hematopoietic stem cell engraftment. [less ▲]

Detailed reference viewed: 90 (36 ULiège)
See detailImpact of Imatinib on immune function in vitro
Pirson, Laurence ULiege; Baron, Frédéric ULiege; Gothot, André ULiege et al

Poster (2006)

Detailed reference viewed: 27 (2 ULiège)
Full Text
Peer Reviewed
See detailTraitement moléculaire du cancer: le STI571, un inhibiteur des tyrosines kinases
Humblet-Baron, Stéphanie ULiege; Baron, Frédéric ULiege; Pirson, Laurence ULiege et al

in Revue Médicale Suisse (2002), 60(598), 1504-1508

Detailed reference viewed: 120 (20 ULiège)